Chugai Releases New Actemra Data, Rides Wave To Submit U.S. FDA Response In Third Quarter
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical, the Japanese division of Roche, June 10 released new data on rheumatoid arthritis drug Actemra (tociluzumab), which showed that up to 56 percent of patients with active RA treated with Actemra for more than two years achieved disease remission. Presented at the European League Against Rheumatism annual congress, the remission data provides Roche and Chugai refreshed vigor on its push for still-pending U.S. approval for tociluzumab
You may also be interested in...
Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Countering the rush out of Japan's discovery research sector, a few global pharmaceutical corporations are maintaining early research operations or even expanding their presence in this area.
Despite A Wide Retreat From Discovery Research By Multinationals In Japan, Some Are Staying Put (Part 2 Of 3)
Countering the rush out of Japan's discovery research sector, a few global pharmaceutical corporations are maintaining early research operations or even expanding their presence in this area.
Chugai Discloses Actemra Adverse Events In Japan – Will It Impact U.S. Approval?
Chugai Pharmaceutical, the Japanese division of Roche, disclosed that rheumatoid arthritis treatment Actemra (tocilizumab) might have been a causal factor in the death of 15 patients in Japan, reported Japanese media March 18.